<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Endo Pharmaceuticals Holdings Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/endo-pharmaceuticals-holdings-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(DTG) Company News for December 13, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/12/13/dtg-company-news-for-december-13-2011-corporate-summary/88499</link>
		<comments>http://www.stockbloghub.com/2011/12/13/dtg-company-news-for-december-13-2011-corporate-summary/88499#comments</comments>
		<pubDate>Tue, 13 Dec 2011 18:37:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Rental & Leasing Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[Cheniere Energy Inc]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[LNG]]></category>
		<category><![CDATA[Martin Marietta Materials Inc.]]></category>
		<category><![CDATA[MLM]]></category>
		<category><![CDATA[Sara Lee Corporation]]></category>
		<category><![CDATA[SLE]]></category>
		<category><![CDATA[VMC]]></category>
		<category><![CDATA[Vulcan Materials Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88499</guid>
		<description><![CDATA[•    Car rental company Dollar Thrifty Automotive Group (NYSE:DTG) said the company&#8217;s CEO and President Mr. Scott L. Thompson will take over the role of Chairman of the Board of Directors with immediate effect. He succeeds Richard W Neu who will assume the role of Lead Independent Director •    Food and beverage company Sara Lee (NYSE:SLE) announced it had purchased Amsterdam based beverage chain CoffeeCompany which consists of 35 cafe bars •    Shares of energy company Cheniere Energy Inc. (AMEX:LNG) gained 5.46% a share after one of the company&#8217;s subsidiary concluded an agreement to sell natural gas to Indian gas transmission and marketing company Gail Ltd •    Drug maker Endo Pharmaceuticals Holdings Inc.’s (NASDAQ:ENDP) share prices increased 5.97%  to close at $36.04 after the company said U.S. Food and Drug ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/13/dtg-company-news-for-december-13-2011-corporate-summary/88499/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan and Endo Pharmaceuticals in Legal Tussle</title>
		<link>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630</link>
		<comments>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630#comments</comments>
		<pubDate>Thu, 18 Aug 2011 22:40:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81630</guid>
		<description><![CDATA[Mylan Inc. (MYL) recently announced that Endo Pharmaceuticals (ENDP) filed a patent infringement lawsuit in connection with an abbreviated new drug application (ANDA) filed by Mylan with the US Food and Drug Administration (FDA) for the generic version of Endo’s acute migraine drug Frova. Mylan believes it is the first company to file an ANDA for generic Frova and is expecting to be granted 180 days of marketing exclusivity once approved. Frova generated revenues of approximately $68.2 million in the trailing twelve months ending on June 30, 2011. This month, Mylan launched the generic version of Uroxatral tablets. Some important products launched by Mylan in the recent past include generic versions of AstraZeneca&#8216;s (AZN) Entocort, Novartis&#8216; (NVS) Femara and Cephalon&#8216;s (CEPH) Amrix. Mylan has a robust generic pipeline. As of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/myl-mylan-and-endo-pharmaceuticals-in-legal-tussle/81630/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals&#8217; Back Pain Drug Disappoints</title>
		<link>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262</link>
		<comments>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:04:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78262</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently suffered a pipeline setback with its candidate axomadol performing disappointingly in a mid-stage trial (n=236). Top line results from the study revealed that Endo Pharma’s candidate failed to meet the predetermined end points. The randomized, double blind, two-arm, placebo-controlled study evaluated the candidate in patients suffering from moderate-to-severe chronic low back pain. Endo Pharma in-licensed the US and Canadian development and marketing rights of axomadol from Grunenthal in 2009. The 4-week study evaluated the candidate at doses ranging from 100 mg/day to 300 mg/day. The maintenance phase of the study was 12 weeks. The main goal was a change in the average intensity of pain measured by a numerical rating scale from baseline to the final week of treatment for all patients who were treated with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/endp-endo-pharmaceuticals-back-pain-drug-disappoints/78262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Announces FDA Action Date</title>
		<link>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598</link>
		<comments>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:46:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77598</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) recently announced that the US Food and Drug Administration (FDA) has issued a new action date for the new formulation of painkiller Opana ER. The FDA stated that it will review Endo Pharma’s response to the agency’s complete response letter (CRL) by December 13, 2011. The new formulation of Opana ER is designed to resist attempts of crushing, breaking, pulverizing or making a powder of the product. The candidate aims to bring relief to patients suffering from moderate-to-severe pain and in need of continuous opioid treatment for an extended period of time. CRL Issued in January 2011 On January 7, 2011, Endo Pharma announced that the FDA had issued a CRL for the painkiller. Even though the US regulatory body declined to approve the new formulation of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/endp-endo-pharmaceuticals-announces-fda-action-date/77598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings Buys American Medical</title>
		<link>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023</link>
		<comments>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023#comments</comments>
		<pubDate>Wed, 22 Jun 2011 14:55:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77023</guid>
		<description><![CDATA[Recently, Endo Pharmaceuticals Holdings Inc. (ENDP) completed the purchase of American Medical Systems, a leading pelvic-health device provider, in an all cash deal worth approximately $2.9 billion. By acquiring American Medical, Endo Pharma, a US-based specialty healthcare solutions company that develops branded products and specialty generics, diversified its business and bolstered its urology portfolio. Endo Pharma, while announcing the deal in April 2011, stated that it expected the deal to be accretive to its adjusted earnings with immediate effect following the closure. Endo Pharma had also announced that it expected its 2012 and 2013 adjusted earnings to be boosted by $0.60 and $0.80 per share respectively, as a result of the merger. We note that the purchase of American Medical is the fourth major acquisition for Endo Pharma over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/22/endp-endo-pharmaceuticals-holdings-buys-american-medical/77023/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems Starts Implant Registry</title>
		<link>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861</link>
		<comments>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861#comments</comments>
		<pubDate>Tue, 21 Jun 2011 04:15:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76861</guid>
		<description><![CDATA[Leading pelvic-health devices maker American Medical Systems (AMMD) recently initiated a large-scale global registry of penile prosthetic outcomes. The new registry, dubbed PROPPER (Prospective Registry of Outcomes with Penile Prosthesis for Erectile Restoration), is managed by a crew of eminent urologists looking to better characterize patient satisfaction associated with modern penile prosthetic implants. The multi-year company-sponsored PROPPER registry, essentially the first-of-its-kind, has been designed to better understand the real-world outcomes of penile implant surgery to treat erectile dysfunction (“ED”). The registry is expected to enroll more than 1,000 ED patients recommended for penile prosthesis by their physicians. The research, which will initially engage ten sites, will involve  a prospective measure of patient responses by investigating physicians at regular intervals (over a 1-5 year period) using questionnaires and electronic data collection. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/20/ammd-american-medical-systems-starts-implant-registry/76861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362</link>
		<comments>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362#comments</comments>
		<pubDate>Mon, 30 May 2011 15:24:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74362</guid>
		<description><![CDATA[We are maintaining our Neutral stance on Endo Pharmaceuticals (ENDP) with a target price of $44.00. Headquartered in Chadds Ford, Pennsylvania and founded in 1997, Endo Pharma is a specialty healthcare solutions company. The company, which operates in the US, reports results through three segments: Branded Pharmaceuticals, Generics and Devices and Services. Endo Pharma offers more than 175 products in the areas of pain management, urology and oncology. In April 2011, Endo Pharma reported its first quarter 2011 results. First quarter adjusted earnings of $1.00 per share were in line with the Zacks Consensus Estimate but $0.26 above the year ago figure. The year-over-year rise in earnings was attributable to the higher revenues reported in the first quarter of 2011. We note that Endo Pharma is on an acquisition spree ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/30/endp-endo-pharmaceuticals-evenly-poised/74362/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMMD) American Medical Systems Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777</link>
		<comments>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777#comments</comments>
		<pubDate>Tue, 10 May 2011 21:01:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BCR]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Cr Bard Inc]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73777</guid>
		<description><![CDATA[We maintain our Neutral recommendation on leading pelvic-health devices maker American Medical Systems (AMMD). Its first-quarter fiscal 2011 earnings of 33 cents per share beat the Zacks Consensus Estimate of 30 cents. Both revenues and profit rose roughly 4% year over year on the back of higher sales from the Minnesota-based company’s men’s health and women’s health businesses, assisted by a healthy contribution from its international operation. Sales (of $140.8 million) for the quarter also beat the Zacks Consensus Estimate. American Medical’s men’s health division remained on the growth track supported by the strength at its male continence business. Its benign prostatic hyperplasia (“BPH”) therapy business posted healthy growth in the quarter, led by the GreenLight XPS laser therapy and the next-generation BPH therapy system MoXy Liquid Cooled Fiber. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/ammd-american-medical-systems-analyst-maintains-neutral-rating-on-shares/73777/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Laboratories Earns FDA Approval of AndroGel</title>
		<link>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465</link>
		<comments>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465#comments</comments>
		<pubDate>Fri, 06 May 2011 01:36:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73465</guid>
		<description><![CDATA[Abbott Laboratories (ABT) recently gained US Food and Drug Administration (FDA) approval for AndroGel (testosterone gel) 1.62%. The gel formulation is approved for the treatment of hypogonadism (low or zero testosterone levels) in adult men. Abbott Labs already has a product in its portfolio for this indication – AndroGel 1%. However, Abbott Labs said that AndroGel 1.62% has the ability to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%. Results from a study showed that 82% of patients taking AndroGel 1.62% achieved a normal average testosterone level on day 112. AndroGel 1.62% will be available from the second quarter of 2011. AndroGel 1.62% became a part of Abbott Labs’ portfolio with its Feb 2010 acquisition of Solvay Pharmaceuticals. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/05/abt-abbott-laboratories-earns-fda-approval-of-androgel/73465/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings to Take Over American Medical Systems</title>
		<link>http://www.stockbloghub.com/2011/04/12/endp-endo-pharmaceuticals-holdings-to-take-over-american-medical-systems/71287</link>
		<comments>http://www.stockbloghub.com/2011/04/12/endp-endo-pharmaceuticals-holdings-to-take-over-american-medical-systems/71287#comments</comments>
		<pubDate>Tue, 12 Apr 2011 20:33:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71287</guid>
		<description><![CDATA[In a bid to diversify its business and bolster its urology portfolio, Endo Pharmaceuticals Holdings Inc. (ENDP), a US-based specialty healthcare solutions company which develops branded products and specialty generics, will purchase American Medical Systems (AMMD), a leading pelvic-health devices provider, for $2.9 billion or $30.00 per share in cash. The offer price is 34% above the April 8, 2011, closing price of American Medical. The $2.9 billion consideration includes the assumption of a $312 million debt by Endo Pharma. The deal, expected to close in the third quarter of 2011, has been approved by the boards of both companies. Endo Pharma anticipates the deal to be accretive to its adjusted earnings with immediate effect following closure. Moreover, the deal is expected to boost Endo Pharma’s 2012 and 2013 adjusted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/12/endp-endo-pharmaceuticals-holdings-to-take-over-american-medical-systems/71287/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Company News for April 12, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270</link>
		<comments>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270#comments</comments>
		<pubDate>Tue, 12 Apr 2011 17:57:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[American Medical Systems Holdings Inc]]></category>
		<category><![CDATA[AMMD]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Community Health Systems Inc.]]></category>
		<category><![CDATA[CYH]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[FLO]]></category>
		<category><![CDATA[Flowers Foods Inc.]]></category>
		<category><![CDATA[GLBC]]></category>
		<category><![CDATA[Global Crossing Limited]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Level 3 Communications Inc.]]></category>
		<category><![CDATA[LVLT]]></category>
		<category><![CDATA[Tasty Baking Company]]></category>
		<category><![CDATA[Tenet Healthcare Corporation]]></category>
		<category><![CDATA[THC]]></category>
		<category><![CDATA[TSTY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71270</guid>
		<description><![CDATA[• Level 3 Communications (NASDAQ:LVLT) and Global Crossing Limited (NASDAQ:GLBC) have entered into a agreement under which Level 3 will acquire Global Crossing in a stock-for-stock transaction • Endo Pharmaceuticals&#8217; (NASDAQ:ENDP) said that it would buy urological medical device supplier American Medical Systems (NASDAQ:AMMD) for about $2.6 billion • Alcoa (NYSE:AA) reported Q1 EPS of $0.28, ex-items, ahead of the Zacks Consensus Estimate of $0.27 per share. Revenues for the quarter rose 22% year-over-year to $6.0 billion, lower than the Zacks Consensus Estimate of $6.112 billion • Share prices of Molycorp, Inc. (NYSE:MCP) increased 5% after JP Morgan (NYSE:JPM) raised its target price to $90 from $74 • Credit Suisse upgraded BHP Billiton (NYSE:BHP) to ‘Outperform’ from ‘Neutral’ rating. Share prices of BHP Billiton gained 1.34% to close at $102.68 • Flowers Food Inc. (NYSE:FLO) said ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/12/aa-company-news-for-april-12-2011-corporate-summary/71270/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly&#8217;s Axiron Testosterone Deficiency Drug Launched in the U.S.</title>
		<link>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638</link>
		<comments>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638#comments</comments>
		<pubDate>Tue, 05 Apr 2011 15:52:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70638</guid>
		<description><![CDATA[Eli Lilly and Company (LLY) recently announced the availability of Axiron in pharmacies across the US. Axiron gained approval from the US Food and Drug Administration (FDA) in November 2010 for use as a replacement therapy in men for certain conditions associated with testosterone deficiency or absence. Axiron Rights Acquired in March 2010 Eli Lilly acquired exclusive worldwide rights from Australian company, Acrux, to commercialize Axiron in March 2010. Per the terms of the deal, Eli Lilly made an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. The FDA approval of Axiron triggered a milestone payment of $87 million from Eli Lilly. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Men’s Health Portfolio ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/05/lly-eli-lillys-axiron-testosterone-deficiency-drug-launched-in-the-u-s/70638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(APC) Company News for December 30, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/12/30/apc-company-news-for-december-30-2010-corporate-summary/64200</link>
		<comments>http://www.stockbloghub.com/2010/12/30/apc-company-news-for-december-30-2010-corporate-summary/64200#comments</comments>
		<pubDate>Thu, 30 Dec 2010 15:45:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Independent Oil & Gas]]></category>
		<category><![CDATA[Anadarko Petroleum Corporation]]></category>
		<category><![CDATA[APC]]></category>
		<category><![CDATA[BHP]]></category>
		<category><![CDATA[Bhp Billiton Limited]]></category>
		<category><![CDATA[Boston Properties Inc.]]></category>
		<category><![CDATA[BXP]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Global Payments Inc]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GPN]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[LMT]]></category>
		<category><![CDATA[Lockheed Martin Corporation]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PEG]]></category>
		<category><![CDATA[Public Service Enterprise Group Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64200</guid>
		<description><![CDATA[• BHP Billiton (NYSE:BHP) plans to offer a price of $90 per share for Anadarko (NYSE:APC) • Lockheed Martin (NYSE:LMT) was awarded a Navy contract yesterday to build 10 warships  known as Littoral Combat Ships, between now and 2015 worth up to $3.6 billion • Susquehanna increased its target price of Global Payments (NYSE:GPN) from $47 to $55, and  maintained its positive outlook • Credit Suisse (NYSE:CS) lowered their earnings projections for both Goldman Sachs (NYSE:GS) and Morgan Stanley (NYSE:MS), keeping an &#8220;outperform&#8221; rating with a price target of $190 for Goldman and $35 for Morgan Stanley • Jefferies (NYSE:JEF) has maintained a &#8220;buy&#8221; rating on Public Service Enterprise (NYSE:PEG) • Boston Properties (NYSE:BXP) has completed the purchase of John Hancock Tower for $930 million • Endo Pharmaceuticals (NASDAQ:ENDP) received FDA approval for Fortesta, which is its ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/30/apc-company-news-for-december-30-2010-corporate-summary/64200/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News for September 28, 2010 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2010/09/28/aapl-company-news-for-september-28-2010-corporate-summary/52889</link>
		<comments>http://www.stockbloghub.com/2010/09/28/aapl-company-news-for-september-28-2010-corporate-summary/52889#comments</comments>
		<pubDate>Tue, 28 Sep 2010 15:34:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[D]]></category>
		<category><![CDATA[Dominion Resources Inc.]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Jabil Circuit Inc.]]></category>
		<category><![CDATA[JBL]]></category>
		<category><![CDATA[Las Vegas Sands Corporation]]></category>
		<category><![CDATA[LVS]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>
		<category><![CDATA[SON]]></category>
		<category><![CDATA[Sonoco Products Company]]></category>
		<category><![CDATA[Target Corporation]]></category>
		<category><![CDATA[TGT]]></category>
		<category><![CDATA[WAG]]></category>
		<category><![CDATA[Walgreen Company]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=52889</guid>
		<description><![CDATA[• Walgreen (NYSE:WAG) reported better-than-expected fiscal fourth quarter earnings of 49 cents a share, five cents higher than estimates, on revenues of $16.87 billion, up 7.4% versus last year • Jabil Circuit (NYSE:JBL) posted fiscal fourth quarter earnings of 52 cents a share, three cents above estimates, on inline revenues of $3.9 billion, 37.9% above a year earlier • Research In Motion Ltd. (NASDAQ:RIMM) announced the Blackberry PlayBook, a new tablet computer, which is set for first quarter 2011 release • Apple (NASDAQ:AAPL) showed advance orders for its iPhone 4 topped 200,000 units in China • Endo Pharmaceuticals (NASDAQ:ENDP) announced plans to buy privately-held generics firm Qualitest for $1.2 billion • KeyBanc upgraded Las Vegas Sands (NYSE:LVS) from &#8220;underperform&#8221; to &#8220;hold&#8221; • Credit Suisse (NYSE:CS) downgraded Target (NYSE:TGT) from &#8220;outperform&#8221; to &#8220;neutral,&#8221; taking the price target from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/28/aapl-company-news-for-september-28-2010-corporate-summary/52889/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Holdings to Buy Penwest Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631</link>
		<comments>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631#comments</comments>
		<pubDate>Fri, 20 Aug 2010 15:44:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Penwest Pharmaceuticals Company]]></category>
		<category><![CDATA[PPCO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48631</guid>
		<description><![CDATA[In a bid to sustain and drive growth in the area of pain management, Endo Pharmaceuticals Holdings Inc. (ENDP) recently agreed to acquire drug developer Penwest Pharmaceuticals Co. (PPCO). Through this deal, Endo Pharma will gain full access to a painkiller that was being co-developed by the companies. The deal, worth approximately $144 million or $5.00 per share in cash, has been approved by the Boards of both companies. The companies have been co-developing an extended-release version of Opana (Opana ER) for treating moderate to severe pain in patients in need of continuous opioid treatment. Under the terms of the agreement, Endo will commence an all-cash tender offer shortly to purchase all the outstanding common stock of Penwest. The tender offer price of $5.00 per share represents a premium of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/20/endp-endo-pharmaceuticals-holdings-to-buy-penwest-pharmaceuticals/48631/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals &#8211; PEG Ratio Also Shows a Bargain at 0.7</title>
		<link>http://www.stockbloghub.com/2010/04/05/endp-endo-pharmaceuticals-peg-ratio-also-shows-a-bargain-at-0-7/32718</link>
		<comments>http://www.stockbloghub.com/2010/04/05/endp-endo-pharmaceuticals-peg-ratio-also-shows-a-bargain-at-0-7/32718#comments</comments>
		<pubDate>Mon, 05 Apr 2010 18:15:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32718</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) continues to trade at great valuations and have plenty of earnings momentum. Company Description Endo Pharmaceuticals makes branded and generic drugs to treat and manage pain. The Pennsylvania-based company has about 1,200 employees and a market cap of $2.6 billion. Still a Great Value Estimates surged after Endo reported its quarterly results in February, now projecting 12% growth this year. The Zacks Consensus rose 31 cents on the news, to $3.17. Shares of ENDO are exchanging hands at just 7.5 times this years estimate. The PEG ratio also shows a bargain at 0.7 times. The Chart Endo&#8217;s share prices had been soaring until a sell of in late March, which came on no news. However, with the fundamentals and valuations still looking good, investors are using this ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/endp-endo-pharmaceuticals-peg-ratio-also-shows-a-bargain-at-0-7/32718/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(LLY) Eli Lilly and Company Expands Men&#8217;s Health Range</title>
		<link>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935</link>
		<comments>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:27:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[BioSante Pharmaceuticals Inc]]></category>
		<category><![CDATA[BPAX]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Repros Therapeutics Inc]]></category>
		<category><![CDATA[RPRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30935</guid>
		<description><![CDATA[Eli Lilly and Co. (LLY) recently entered into a deal with Australian company, Acrux, which should help strengthen Lilly’s men’s health portfolio. Lilly acquired exclusive worldwide rights to commercialize Axiron, which is currently being reviewed by the US Food and Drug Administration (FDA) for the treatment of testosterone deficiency (hypogonadism) in men. As per the terms of the deal, Lilly will make an upfront payment of $50 million and $3 million on the transfer of manufacturing assets. Lilly will also pay $87 million to Acrux on the receipt of FDA approval for the product. Acrux could receive up to $195 million in commercialization milestones, and royalty payments on global sales of the product. Lilly expects to incur a charge of 3 cents related to this transaction in the first quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/lly-lly-expands-mens-health-range/30935/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENDP) Endo Pharmaceuticals Hits FDA Roadblock With Aveed</title>
		<link>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623</link>
		<comments>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623#comments</comments>
		<pubDate>Fri, 11 Dec 2009 22:32:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Auxilium Pharmaceuticals Inc.]]></category>
		<category><![CDATA[AUXL]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22623</guid>
		<description><![CDATA[Endo Pharmaceuticals (ENDP) hit a roadblock related to the approval of Aveed. Recently, the company received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its injectable testosterone product Aveed for men diagnosed with low testosterone, also known as hypogonadism. The FDA is concerned about the adverse events including post-injection anaphylactic reaction and pulmonary oil microembolism. In the CRL, the company has been asked to address these concerns. Additionally, the FDA has made it clear that it is not satisfied with the proposed Risk Evaluation and Mitigation Strategy (REMS) adopted by the company. Aveed, known as Nebido outside the US, has been approved in 86 countries worldwide and is available in more than 50 countries across Europe, Asia Pacific ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/11/endp-endo-pharmaceuticals-hits-fda-roadblock-with-aveed/22623/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

